An interventional study of ReLEx and LASIK in Astigmatism, sponsored by Aarhus University Hospital. Withdrawn at 1 site in Denmark. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2014-05-02.
Sponsored by Aarhus University Hospital · Not applicable, Interventional, and Treatment
Laser correction for myopia and astigmatism using an excimer laser has been performed with success for several years.
During the last 2 years, a new method for correction of refractive errors has emerged. In the method (ReLex) a femtosecond laser is used to cut a lenticule in the corneal stroma that is subsequently removed. For simple myopia this method has proved effective and on par with excimer baser LASIK. However, it remains to be determined if ReLEx is as effective in the treatment of astigmatism.
In the study, patients with high astigmatism are treated with conventional LASIK for astigmatism in one eye and with ReLEx for astigmatism in the other.
413 studies on the registry are indexed under Astigmatism; 55 are open to participants now.
Browse Astigmatism studies →Aarhus University Hospital is the lead sponsor of 289 studies on the registry; 79 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
One eye is treated with ReLEx the other with LASIK
Procedure: ReLEx
One eye is treated with ReLEx the other with LASIK
Procedure: LASIK
Also known as: Device: Carl Zeiss Meditec Visumax Femtosecond Laser
Also known as: Device: Carl Zeiss Meditec MEL-80 excimer laser
Visual acuity
Time frame: 1 year
Refraction
Time frame: 1 year
This study is withdrawn, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aarhus University Hospital